Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that President and Chief Executive Officer Todd C. Brady, M.D., Ph.D., will participate in an ophthalmology panel discussion during Citi’s 15th Annual BioPharma Virtual Conference, taking place September 8-11, 2020. In addition, Aldeyra’s senior management will host one-on-one meetings at the conference.
Title: Seeing 20/20 in 2020
Date: Thursday, September 10, 2020
Time: 9:50 a.m. ET
A live webcast of the panel discussion will be available on the investor relations page of the company’s corporate website at https://ir.aldeyra.com. After the live webcast, the event will remain archived on the Aldeyra Therapeutics website for 90 days.
About Aldeyra Therapeutics
Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease and result in cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company’s clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer. For more information, visit https://www.aldeyra.com/ and follow us on LinkedIn, Facebook, and Twitter.
Aldeyra Therapeutics, Inc.
Tel: 781-761-4904 ext. 218